CDHP inhibits the activity of dihydropyrimidine dehydrogenase (DPD), an enzyme that degrades 5-FU, with about 180-fold more potency than uracil, thereby maintaining prolonged blood and tumour 5-FU concentrations. The gene discussed is CDH3; the disease is neoplasm.